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Abstract
Background:  The infectious pathway of the non-enveloped Human Papillomavirus Type 16
(HPV16) includes binding to the cell surface, clathrin-mediated endocytosis, and penetration into
an endosome. HPV16 infection was shown to decrease in the presence of the lysosomotrophic
neutralizing agent ammonium chloride (NH4Cl). NH4Cl neutralizes acidic endo-lysosome
compartments, thus suggesting that pH was responsible for PV capsid conformational changes
leading endosome escape.
Results: However, our data suggested that NH4Cl blocked infection by preventing the movement
of PV viral particles from the early endosome to the caveosome as was shown for JC virus [1,2].
We have confirmed that HPV 16 infection requires the trafficking of reporter-virions to the
caveosome as is the case for BPV1 [3,4]. In this manuscript we propose that the observed decrease
in infection of PV in the presence of NH4Cl was due to a loss of movement of reporter-virions to
caveosomes. We also demonstrate that cysteine proteases are involved in the infectious process,
and that cathepsin B treatment of viral particles was shown to overcome the block of infection
observed in the presence of furin inhibition. We confirmed the need for cathepsin B in HPV16
infection using cathepsin B null mouse embryonic fibroblasts.
Conclusion: We present data that suggest HPV16 infection is in part mediated by cysteine
proteases, and that NH4Cl blocks the intracellular trafficking of infectious viral particles. To our
knowledge this is the first demonstration that cysteine proteases influence the infection of a non-
enveloped virus.
Background
Human Papillomaviruses (HPVs) are non-enveloped
DNA viruses that can infect the skin and mucous mem-
branes. HPVs are known to cause cutaneous, cervical, and
respiratory warts and lesions [5-7]. The capsid of HPVs is
made of two virally encoded structural proteins L1 and L2
[8-10]. The major capsid protein L1 is primarily involved
in attachment of the virus to the plasma membrane, while
the minor capsid protein L2 functions in viral genome
trafficking and encapsidation [11-15].
The infectious process begins via virion attachment to the
cell surface through breaks in the skin. Although the vir-
ion-cell binding process is still unclear it is thought to
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occur by initial binding of the L1 protein on the virion
capsid to heparan sulfate (a cell surface proteoglycan), fol-
lowed by binding to a secondary receptor, putatively an
integrin complex [16-18]. α6β4 has been shown to be
able to mediate cell binding in studies showing that anti-
bodies against α6 could block virion binding to the epi-
thelial cells CV-1 and HaCaT keratinocytes [19]. However,
α6β4 integrin may not be a necessary requirement for
infection since studies also indicate that some PVs can
infect cells such as BO-SV keratinocytes that lack this com-
plex [20]. After attachment to the cell surface the HPV16
virion is internalized via a mechanism that begins with
clathrin mediated endocytosis [2,21,22]. N-terminus
cleavage of L2 by furin, a calcium dependent serine endo-
protease found at the plasma membrane, Golgi and endo-
somes, has been suggested to be required for infection
[23,24]. Our data suggests that after trafficking to the
endosome, the reporter-virions may follow either an
infectious route or a noninfectious route ([3,4]). In the
infectious route, reporter-virions are moved to the caveo-
lin-1 intracellular sorting pathway. This caveolin-1 path-
way was shown to be necessary for infection, as infection
is blocked in cells where caveolin-1 protein levels were
reduced using siRNA against caveolin-1 ([3,4]). After
entering the caveosome, the virion was shown to traffic in
an L2-mediated event to a region where it colocalized with
the endoplasmic reticulum (ER) t-SNARE syntaxin 18 and
the ER chaperone calnexin and ERp29 ([3,4,11,14]). The
non-infectious pathway results in trafficking from the
endosome to the lysosome where reporter-virions may be
processed for degradation by the cell. This latter pathway
was shown using a non-infectious L2 mutant virus and
neutralizing antibodies [3]. It has been shown that
ammonium chloride (NH4Cl) blocks infection of Bovine
Papillomavirus Type 1 (BPV1), a PV with similar kinetics
to HPV16 [2]. NH4Cl neutralized the acidic endo-lyso-
some compartments suggesting that pH was responsible
for PV capsid conformational changes leading to viral
genome release. However, our data presented in this man-
uscript suggested that ammonium chloride blocked infec-
tion by preventing the movement of viral particles from
the early endosome to the caveosome as was also shown
for JC virus [1]. In this manuscript we show that cysteine
proteases and not pH may be responsible for changes
leading to infection.
Cysteine proteases function as intracellular and extracellu-
lar molecules [25]. The cysteine protease cathepsin B is
associated with caveolae. Caveolae are defined as small
invaginations of the plasma membrane associated with
lipid rafts that contain caveolin-1 [26,27]. Similar to cave-
olae, endo-lysosomal compartments within cells contain
cathepsin B but in addition have cathepsin L. Both of
these cathepsins are zymogens (pro-forms) that are
cleaved into their active form [28,29]. The exact mecha-
nism of activation is not well understood however, activa-
tion of pro-cathepsin B may occur by S100A10, a protein
found in caveolae, while activation of pro-cathepsin L
may occur by heparan sulfate, a possible receptor for PV
[27,30]. In addition to caveolae and endosomes, cathep-
sins have been found to be associated with lipid rafts, sug-
gesting that cathepsins may be needed upon
internalization to break apart matrices on viral surfaces
[25].
Cathepsins B and L have been implicated in the mecha-
nism of binding, entry and disassembly of several envel-
oped viruses. In the case of binding, treating Ebolavirus
reporter-virions with cathepsin L enhanced infectivity by
cleaving and removing a highly glycosylated mucin
domain in the Ebolavirus glycoprotein and resulted in
increased binding suggesting that cathepsins are indeed
present on the cell membrane [31]. Fusion of enveloped
viruses such as Nipah, Hendra, SARS Coronavirus and
Murine Coronavirus Mouse Hepatitis Virus has been
shown to be dependent on cathepsins B and L. In Nipah
virus, both cathepsin B and L were shown to cleave a
membrane fusion protein required for virus-cell and cell-
cell membrane fusion. Cleavage of the viral membrane
fusion protein into the correct size was necessary for mat-
uration into a fusogenic form. Cathepsin B was shown to
cleave the fusion protein in a cell-free system into two
fragments but the smaller of these fragments migrated
slower than fragments produced during the cleavage that
occurs in infection, suggesting that the fusion protein was
not cleaved at the correct size. Cathepsin L was able to
cleave the fusion protein into fragments of the correct size
in the cell-free system suggesting that although cathepsin
B and L are catalytically similar, they may have distinct tar-
get/sequence specificity [32]. Similar to Nipah virus,
cathepsin L was involved in cleaving the Hendra virus
fusion protein into an active heterodimer [33]. In SARS
Coronavirus infection, cathepsin L was needed to cleave
the spike protein, one of four major structural proteins,
into two subunits: one having a high binding affinity to
the receptor and the other mediating fusion of viral and
cellular membranes [34]. The requirement of cathepsins
for fusion was also shown in Murine Coronavirus Mouse
Hepatitis Virus (MHV), where proteolysis by cathepsin B
and L was necessary for cleavage of the MHV-2 spike pro-
tein [35]. In addition, proteolysis by cathepsins was
shown to be important for disassembly of Reovirus. Using
mouse embryonic fibroblasts derived from cathepsin B or
L deficient and wild type mice, studies show that Reovirus
disassembly was prohibited in the absence of cathepsins B
and L [36].
In this manuscript, we show a role for cathepsin B that
may be important for HPV16 infection. It is, to our knowl-Virology Journal 2009, 6:109 http://www.virologyj.com/content/6/1/109
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edge, the first description of the role of cysteine proteases
on a non-enveloped virion.
Results
Cysteine protease inhibitors inhibit HPV16 infection
To determine the role of cysteine proteases on HPV16
infection, we performed infections of 293 cells in the pres-
ence of protease inhibitors at non-toxic concentrations
[see Additional file 1] and compared them to the loss of
infection in the presence of the lysosome pH neutralizing
agent ammonium chloride (NH4Cl). The dose dependent
concentration effects of the inhibitors on HPV16 infection
are also shown [see Additional file 2]. Infection by HPV16
DsRed reporter-virions was determined by FACS analysis
of DsRed fluorescent cells after 48 hours. Compared to
cells infected in the absence of inhibitor (Fig 1, infected
bar), we observed a 61.45% decrease in infection the pres-
ence of NH4Cl (Fig 1, NH4Cl bar), a 41.38% and 37.30%
decrease in the presence of permeable and non-permeable
broad targeting cysteine protease inhibitors (Fig. 1, E64
and E64-d bar, respectively), and a statistically significant
decrease in infectivity of 53.75% and 51.11% in the pres-
ence of specific cathepsin B or cathepsin L inhibitors (Fig
1 cathepsin B and cathepsin L bars respectively) (p < 0.05
1-tail t test). The experiment was repeated in HaCaT cells
and shows that in the presence of either NH4Cl or the
cysteine protease inhibitor E64, a decrease in infection is
observed compared to cells that were infected in the
absence of inhibitor [see Additional file 3]. These data
suggested a role for cysteine proteases in HPV16 infectiv-
ity.
Ammonium chloride prevents HPV16 trafficking to 
caveosomes
In the presence of NH4Cl HPV16 infection levels were
shown to decrease. To determine if NH4Cl was able to
block the movement of HPV16 reporter-virions from early
endosomes to caveosomes, we infected 293 cells in the
presence or absence of 20 mM NH4Cl. Infection by GFP-
Reporter HPV16 reporter-virions was assessed by confocal
microscopy and stereology counts. Data was collected at 5
minutes post binding for early endosome staining (with
goat anti- EEA1, Fig. 2A and 2B, red) and 2 hours post
binding for caveolin-1 staining (with goat anti-caveolin 1,
Fig 2C and 2D, red). HPV16 particles were stained using a
monoclonal anti-HPV16 L1 antibody H16V.5 (Fig 2A–D,
green). In the absence (Fig 2A) and presence of NH4Cl
(Fig 2B) overlap is observed between HPV16 (Fig 2, green)
HPV16 infection is reduced in the presence of cysteine protease inhibitors Figure 1
HPV16 infection is reduced in the presence of cysteine protease inhibitors. Infection of 293 cells alone, with HPV 16 
DsRed reporter-virions (mock control, Infected), or in the presence of: 20 mM of lysosome neutralizing agent NH4Cl; 10 μM 
of a non-permeable cysteine protease inhibitor E64; 10 μM of the permeable cysteine protease inhibitor E64-d; 6 μM of the 
permeable intracellular cathepsin B inhibitor CA-074ME; or 10 μM of the cathepsin L inhibitor. Infection was analyzed and 
compared 48 hours post binding by FACS of DSRED expression. Inhibitors were present for the duration of infection. Cells 
alone were analyzed for background fluorescence. Statistics were analyzed by 1 tailed t-test and found to be significant at P < 
0.05.
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Ammonium Chloride blocks the trafficking of HPV16 to caveosomes Figure 2
Ammonium Chloride blocks the trafficking of HPV16 to caveosomes. Infection of 293 cells alone in the absence (A 
and C) or presence (B and D) of 20 mM of lysosome neutralizing agent NH4Cl. Cells were harvested after 5 minutes post bind-
ing for early endosome staining with goat anti- EEA1 (A and B), or 2 hours post binding for caveosome staining with goat anti-
caveolin 1 (C and D). HPV16 particles were stained using a monoclonal anti-HPV16 L1 antibody H16V.5 (A-D). Images are 
shown with z-stacks obtained by confocal microscopy. The number of caveosomes (E), HPV16 reporter-virions (E), and colo-
calization between HPV16 and caveosomes (F) in the absence and presence of NH4Cl were counted using stereology software.
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and the early endosomes (Fig 2A and 2B red) as indicated
by the yellow color (Fig 2A and 2B, yellow). We observed
a decrease in colocalization between HPV16 (Fig 2 green)
and caveolin-1 staining (Fig 2C and 2D, red) in the pres-
ence of NH4Cl as compared to the absence of NH4Cl
(compare Fig 2D to Fig 2C, yellow). A comparison of the
percent of HPV16 reporter-virions overlapping with cave-
olin-1 in the absence or presence of NH4Cl by stereology
showed a statistical significant change. The percent of
HPV16 reporter-virions colocalizing with caveosomes
decreased by 65.52% in the presence of NH4Cl (Fig 2F
Caveosomes and HPV16 overlap -NH4Cl, and Caveosome
and HPV16 overlap + NH4Cl). This 65.52% decrease in
colocalization was statistically significant at p < 0.05 1
tailed T test. We did observe a drop in the overall number
of caveosomes, and no changes in the number of internal-
ized viral particles (Fig 2E). The decrease in HPV16 infec-
tivity was not due to the effects of NH4Cl on the HPV16
reporter-virions [see Additional file 4]. These data suggest
that NH4Cl can influence that formation of caveosomes
and of the movement of HPV16 reporter-virions into
caveosomes similar to JC virus.
Cathepsin B treatment of HPV16 increases infection levels
Because cysteine protease inhibitors reduced infection, we
wanted to determine if treating purified HPV16 reporter-
virions with cysteine proteases influenced infection.
HPV16 reporter-virions were treated with cathepsin B or
cathepsin L protease for various amounts of time at 37°C,
added to cells, and infections were analyzed by flow
cytometry after 48 hours (for DsRED expression). Treat-
ment of HPV16 with cathepsin B protease for 15 minutes
increased infectivity compared to untreated reporter-viri-
ons (Fig 3A, 15 min bar vs. infected/w nontreated HPV16
bar) and was observed to increase and peak at 6 hours to
3.09 fold as compared to non-treated HPV16 infections
(Fig 3A, 6 hr bar vs. infected/w nontreated HPV16 bar).
This increase in infection can be considered both statisti-
cally and physiologically significant since the amount of
infection is 3 times greater than in the control. A lesser
increase in infection was observed after 8 and minimal
after 12 hrs (Fig 3A 8, 12 hr bars). Cathepsin L protease
treatment of HPV16 did not enhance infection levels
above untreated reporter-virions (Fig 3B red bar). These
data suggested that treating HPV16 reporter-virions with
cathepsin B protease enhanced infection whereas treat-
ment with cathepsin L did not have an affect. Experiments
were repeated with different reporter virion preparations
with similar results. HPV16 reporter-virions are known to
require a maturation step at 37°C [37]. We incubated
already matured reporter-virions at 37°C throughout the
time course to ensure that any increase in infectivity
observed was not due reporter-virions that were partially
matured further maturing at 37°C (and thus more effi-
cient infection) [see Additional file 5]. Our results indi-
cated that the additional 37°C incubation process did not
significantly change infection levels suggesting that
reporter-virions were matured, i.e., no further virion mat-
uration occurred during the additional 37°C incubation
(p < 0.05, 1-tail t test). Experiments in which cells were
Cathepsin B treatment of HPV16 increases infection Figure 3
Cathepsin B treatment of HPV16 increases infection. HPV16 DsRed reporter-virions were incubated with (A) 37 pM 
cathepsin B protease or (B) 37 pM cathepsin L protease for various amounts of time. 293 cells were infected with protease 
treated reporter-virions or infected with untreated reporter-virions (control). Infections were analyzed by flow cytometry for 
DsRed expression 48 hours post binding. 293 cells alone were used as control for background fluorescence. Statistics were 
analyzed by 1 tailed t-test and found be significant at P < 0.05.
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treated with cathepsin protease prior to infection showed
no changes in infection (data not shown).
Protease treatment of HPV16 increases binding
In order to determine if the increase in infection observed
after protease treatment of reporter-virions was due to
changes in total virus binding, tritium radio-labelled
HPV16 (3H HPV16) binding studies were performed. 3H
HPV16 reporter-virions were incubated with cathepsin B
or cathepsin L protease for various amounts of time,
added to cells and allowed to bind at 4°C for 2 hours
before being thoroughly washed, harvested and fixed for
analysis by scintillation counter. Treatment of HPV16
reporter-virions with cathepsin B protease for 1 hour
increased binding by 1.3 fold compared to the non- pro-
tease treated reporter-virions (Fig. 4A, 1 hr bar) (p < 0.05,
1-tail t test). Cathepsin L protease treatment up to 1 hour
also increased HPV16 binding (1.37 fold) (p < 0.10 1-tail
t test) (Fig. 4B). Maximal binding was observed with 1
hour of treatment with either protease resulting in a 30%
increase in infectivity for cathepsin B treated reporter viri-
ons and 37% increase in infectivity for cathepsin L treated
reporter-virions. Since binding increased by a third, the
difference can be considered physiologically significant in
addition to statistically significant. Binding was observed
to decrease with cathepsin B and L treatments for more
than 1 hour. These data suggest that protease treatment of
HPV16 for 1 hour can increase binding, that longer time
incubation results in a loss of total binding, and that the
increase in infection after protease treatment of reporter-
virions may not be a direct result of increased binding.
Protease treatment of reporter-virions overcomes furin 
inhibition
BPV1 infection has been shown to be dependent on a
furin cleavage event [2,14,24]. This proteolytic event is
thought to occur after an initial conformational change in
the viral capsid [24]. To determine if cysteine proteases
played a role in mediating furin protease cleavage, we
infected cells incubated with a furin inhibitor using
cysteine protease treated reporter-virions. 293 cells were
incubated with furin inhibitor overnight, infected with
HPV16 reporter-virions that were treated for various
amounts of time with cathepsin B or cathepsin L protease,
Cathepsin B and L treatment of HPV16 increases binding Figure 4
Cathepsin B and L treatment of HPV16 increases binding. Reporter virus binding was compared in 293 cells incubated 
with 3H labeled HPV16 reporter-virions treated for various amounts of time with (A) 37 pM cathepsin B protease or (B) 37 pM 
cathepsin L protease. Amount of binding was quantified by scintillation counter for the presence of 3H. Statistics were analyzed 
by 1 tailed t-test and found to be significant at P < 0.05 for (A) and P < 0.10 for (B).
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and infections were analyzed by flow cytometry after 48
hours (for DsRED fluorescence). As previously described
[24], furin inhibition decreased HPV16 infection by
61.39% compared to cells that were infected in the
absence of the furin inhibitor (Fig. 5A, Infected and
Infected + Furin Inhibitor bars). To our surprise, cathepsin
B treated HPV16 reporter-virions for 2 and 4 hours had a
significant increase in infection levels (p < 0.05 1-tail t
test) in the presence of furin inhibitor as compared to
infection of untreated reporter-virions in the presence of
furin inhibitor (compare Fig. 5A 2 and 4 hr bars to
infected + Furin inhibitor bar). Cathepsin B treated
reporter-virions for 2 hours were as infectious in the pres-
ence of furin inhibitor as infected control without pro-
tease treatment or furin inhibition (Compare Fig 5A
Infected and 2, 4 hr bars). Reporter-virions treated with
cathepsin L protease were unable to overcome furin inhi-
bition and were unable to reach levels comparable to that
of the infected control without furin inhibition (Fig 5B)
(p < 0.05 1-tail T test). These data suggested that cathepsin
B but not cathepsin L treatment of HPV16 reporter-virions
can overcome furin inhibition.
HPV16 Infectivity is blocked in the absence of cathepsin B
Because our data suggested that cathepsin B may play a
role in the infection pathway of 293 cells, we were inter-
ested in determining if our observation was cell line spe-
cific. We performed infection experiments using cathepsin
Cathepsin B treatment overcomes block of infection caused by furin protease inhibition Figure 5
Cathepsin B treatment overcomes block of infection caused by furin protease inhibition. 293 cells incubated with 
60 μM of furin inhibitor DEC-RVKR-CMK overnight were infected in the presence of mock treated (control), cathepsin B pro-
tease (A, 37 pM) or cathepsin L protease (B, 37 pM) treated reporter-virions for various amounts of time. Cells were analyzed 
48 hours post binding by flow cytometry for the presence of DsRed expression. Statistics were analyzed by 1 tailed t-test and 
found to have a significant difference at P < 0.05.
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deficient mouse embryonic fibroblast (MEFs) cell lines.
Using the cathepsin knockout MEFs we were able to con-
firm the role of cathepsins because unlike inhibitors
which may have non-specific effects on the host cell and
do not inhibit 100% of the target leading to partial effects
in infectivity, knockout MEFs ensure that cathepsin B or L
were completely absent. MEFs deficient for either cathep-
sin B, cathepsin L, or wild type MEFs, i.e., cathepsin B and
L positive, were infected with HPV16 reporter-virions and
analyzed for infection levels after 48 hours. Compared to
the 46.58% infection in the cathepsin B +/+ wild type
MEFs (Fig 6A, cath B +/+ with HPV16), cathepsin B defi-
cient -/- MEFs were not susceptible to infection, yielding
only 0.80% infection (Fig 6A, cath B -/- with HPV16).
Cathepsin L wild type +/+ MEFs (Fig 6A, cath L +/+ with
HPV16) showed an increase in infection levels (78.38%)
compared to cathepsin L -/- deficient MEFs (Fig 6A, cath L
-/- with HPV16) which had a 60.26% infection level. Cells
alone showed no background levels of autofluorescence
(Fig 6A cells alone bars). The data suggested that cathep-
sin B protease is required for infection of HPV16 in MEFs.
Discussion
Cathepsin proteases have been shown to be able to mod-
ify the binding and entry of many enveloped viruses, and
thus influence infection efficiency [31-36]. In this manu-
script, we broadened the involvement of cathepsin pro-
teases to the non-enveloped virus, HPV16. We showed
that cathepsin proteases play a role in the infection of
HPV16 into human embryonic 293 cells (HEK 293), and
into mouse embryonic fibroblasts (MEFs).
Data previously obtained by our laboratory has demon-
strated that BPV1 and HPV16 infection follow a 'non-clas-
sical' trafficking route post-clathrin-mediated endocytosis
[3,4]. Our data demonstrated that after reporter-virions
have endocytosed using clathrin-coated pits, the reporter-
virions are found in an early endosome (EEA1 positive
vesicle), and are sorted to a caveolin-1 positive organelle
putatively the caveosome before colocalizing with endo-
plasmic reticulum (ER) marker. Caveosome were origi-
nally identified as a necessary component of SV-40
trafficking [38] and subsequent work has demonstrated
that reporter-virions seem to traffic through caveosomes
on their way to the endoplasmic reticulum. In order for
BPV1 and HPV16 to reach the caveosome, there would
have to be cross-talk between endosomes and caveo-
somes. This cross-talk has now been described for JC virus
[1] and for HPV 31 [39]. A commonly used technique that
is used to determine the role of pH and endo-lysosomes
in viral trafficking involves using the lysosome pH neu-
tralizing chemical ammonium chloride (NH4Cl) to pre-
Lack of HPV16 Infection in the absence of cathepsin B Figure 6
Lack of HPV16 Infection in the absence of cathepsin B. HPV16 infection levels in cathepsin B and cathepsin L deficient 
(-/-) and wild type (+/+) MEF cells were analyzed and compared 48 hours post binding by FACS analysis of GFP expression. 
Cells alone were analyzed for background fluorescence. Statistics were analyzed by 1 tailed t-test and found to have a signifi-
cant difference at P < 0.05.
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vent the acidification of vesicles, unfortunately this
treatment also results in the loss of fusion of intracellular
vesicles. In fact, it was shown that NH4Cl prevented the
movement of JC virus from endosome to caveosome.
The observed loss of viral infection using NH4Cl posed
two hypotheses: 1) that the PV infection was preventing
the fusion of vesicles, and 2) that NH4Cl was preventing
the function of endo-lysosome proteases by preventing
their conversion from "pro-inactive" form to "active"
form. Our data shown in Figure 2 confirmed that indeed
there was loss of movement of HPV 16 reporter-virions
from endosomes to caveosome that could account for the
loss of infection observed using NH4Cl (shown in Fig 1).
Regarding the role of endo-lysosome proteases, we
focused on the cysteine proteases cathepsin B and L, two
highly abundant proteases in the endo-lysosome com-
partments, and as mentioned above, cathepsin B and L
have been previously shown to be involved in viral infec-
tions. Our data showed that broad cysteine protease
inhibitors and specific cathepsin B or L inhibitors were
able to decrease infection, thus suggesting that cysteine
proteases were in part mediating HPV16 infection in 293
cells.
Furin protease has been shown to be necessary for viral
infection by allowing the escape of the viral particle from
an endosome (Richards RM, Lowy DR, Schiller JT, Day PM
[24]). Richards and colleagues theorized that furin
allowed the escape of reporter-virions from an endosome
as observed by the loss of endosome marker (EEA1) stain-
ing overlap with reporter-virions. Our data supports a loss
of EEA1 overlap with reporter-virions but show that
reporter-virions are moved to a caveolin-1 vesicle. It is
unclear where Richards and colleagues propose viral par-
ticles escape to. Because furin cleavage was shown to occur
after capsid conformation changes, we addressed if cathe-
psins B or L were playing a role in capsid structural
changes that aided the furin cleavage event. To our sur-
prise the pre-treatment of purified viral particles with
cathepsin B, but not cathepsin L, was able to overcome the
block of infection observed in the presence of furin inhib-
itor. The significance of this finding needs further work. It
is possible that HPV16 utilizes cathepsin B as a "backup"
mechanism for furin in order to establish infection.
In a recent study addressing the role of endosome pro-
teases in the disassembly of HPV16 [24], the authors
negated the role of cathepsin B and L in the HPV16 infec-
tious process. The differences between our studies and
theirs may be due to the variation in inhibitors, cell lines,
and quantity of viral particles used. In the paper by Rich-
ards and colleagues the cathepsin B inhibitor used was
CA-074, a membrane impermeable inhibitor that would
not have shown an effect on an intracellular process (we
used both a permeable and non-permeable inhibitor); the
cathepsin L inhibitor used was only described as "cathep-
sin L inhibitor" and no further conclusions can be drawn
as to the specificity of the inhibitor [24]. In addition, the
observations described by Richards and colleagues were
seen in the HPV 18 positive cervical carcinoma HeLa cells
while our studies were performed in the adenovirus E1A
transformed human embryonic kidney 293 cell line and
in MEFs derived from cathepsin B-deficient mice and
cathepsin L-deficient mice [24]. HeLa cells were recently
shown to be infected by a non-clathrin mediated endocy-
tosis event, a finding that may also explain the differences
in both studies [40]. Finally the experiments performed in
the paper by Richards and colleagues, used a minimum of
7.5 ng of PV while our experiments were carried out using
less than 0.33 ng of HPV16 (1 ng of VLPs has 30 million
particles); a difference that may also contribute to the dif-
ferences in results.
Conclusion
In summary, our data in this manuscript supports that
during the process of infection, HPV16 is subjected to par-
tial proteolysis by cathepsins at the plasma membrane, in
the endo-lysosome, or in the caveolin-1 positive vesicles.
Work pursuing the role of cysteine proteases in HaCaT
keratinocytes and the specific biological significance and
cellular site of cathepsin proteolysis is on-going.
Methods
Cells, antibodies, proteases and inhibitors
293 cells, a human embryonic kidney cell line (HEK),
HaCaT cells, spontaneously immortalized human kerati-
nocytes, and cathepsin B deficient (-/-), wild type (+/+),
cathepsin L deficient (-/-) and wild type (+/+) mouse
embryonic fibroblasts (MEFs) were grown in Dulbecco's
Modified Eagle's medium (DMEM) supplemented with
10% Fetal Bovine Serum (DMEM-10), and 100 IU/mL
penicillin/streptomycin. MEF cells were gifts from Dr. T. S.
Dermody (Vanderbilt University School of Medicine,
Nashville, TN). Goat anti-EEA1 (which recognizes early
endosomes) antibody was purchased from Santa Cruz
Biotechnology, Santa Cruz, CA. Rabbit anti-caveolin 1
antibody was purchased from Cell Signaling Technology
(Danvers, MA). The monoclonal HPV16 L1 antibody,
H16 V.5 was a generous gift from Dr. Neil Christensen
(Penn State University, Hershey, PA). The following
inhibitors were obtained from Calbiochem (Gibbstown,
NJ) and used at the following non-toxic concentration:
CA-074Me (6 μM), Z-FF-FMK an irreversible cell permea-
ble cathepsin L inhibitor (10 μM), E64 (10 μM), E64-d
(10 μM). Furin inhibitor DEC-RVKR-CMK was obtained
from Biomol International (Plymouth Meeting, PA) and
used at the non-toxic concentration of 60 μM. Ammo-
nium chloride was used at a 20 mM concentration as per
Day et al., (Sigma, St. Louis, MO) [2]. Cathepsin B pro-Virology Journal 2009, 6:109 http://www.virologyj.com/content/6/1/109
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tease (Calbiochem) and cathepsin L protease (R&D Sys-
tems Minneapolis, MN) were used at a concentration of
37 pM, a lower concentration compared to Ebert et al.,
[36].
Flow cytometry
Inhibitors were added to 293 cells and allowed to incu-
bate on cells at 37°C with 5% CO2 for 2 hours prior to
infection. After the 2 hr incubation period, the cells were
placed on ice. HPV 16 reporter-virions containing a
DsRed or GFP transgene were added to cells on ice for 2
hours to allow for binding. At 2 hours, inhibitors and
unbound virus were removed by washing with DMEM-10
and replaced with 500 μl of warm DMEM-10 plus inhibi-
tor. MEFs (not treated with inhibitors) were placed on ice
for 2 hours in the presence of HPV16 reporter-virions to
allow for binding. Unbound reporter-virions were
removed by washing with DMEM-10 and replaced with
500 μl of warm DMEM-10. The cells were incubated at
37°C with 5% CO2 for 48 hours. Cells were harvested
using trypsin. The cells were spun for 1 min at 16,100 × G,
the pellet was washed 5× in 1× PBS and resuspended in
300 ul of 1× PBS. 10,000 cells were counted on a fluores-
cence activated cell sorter (FACS) and the number of
DsRed or GFP positive cells was used to determine the per-
cent of infected cells (FACS performed at RFUMS Flow
cytometry core). All experiments were repeated using
reporter-virions made from different preparations.
Immunofluorescence
Cells transfected on coverslips were washed 3× in 1× PBS
and fixed in 4% paraformaldehyde for 20 min at 4°C.
Paraformaldehyde was removed via 3 washes with 1×
PBS. Cells were permeabilized with blocking buffer (0.2%
fish skin gelatin (Sigma) and 0.2% Triton X-100 in PBS)
for 5 min. The coverslips were washed 3× with 1× PBS and
incubated with the appropriate primary antibody at 1:100
dilution in blocking buffer (1:25 dilution for LAMP1 anti-
body). Fluorescence labelled Alexa-flour donkey anti-
mouse 488, goat anti-rabbit 594, chicken anti-goat 594,
(Molecular Probes/Invitrogen, Eugene, OR) were used as
secondary antibodies at 1:2,000 dilution in blocking
buffer in a 30 minute incubation. Coverslips were incu-
bated for 5 minutes with TOPRO-3 (Invitrogen, Carlsbad
CA) at 1:1000 dilution for nuclear staining. The coverslips
were mounted on glass slides using Prolong anti-fade
mounting medium (Invitrogen). Fluorescence confocal
microscopy and stereology (the quantification of the per-
centage of colocalization observed in the image, i.e.
merged colors) were performed using an Olympus
Fluoview 300 microscope, and analyzed with Fluoview
and stereology software (Olympus, Melville, NY) at the
microscopy core of Rosalind Franklin University of Medi-
cine and Science (RFUMS) (North Chicago, IL). All
images are shown with z stacks.
Cytotoxicity Assay
Cytotoxicity studies for the various inhibitors were carried
out using the CellTiter-Glo Luminescent Cell Viability
Assay Kit (Promega, Madison, WI). Cells were incubated
with various concentrations of inhibitors for 48 hours and
then the supernatant and trypsinized cells were collected.
100 μl of the harvested cell suspension was added to a
well in a 96-well plate. The CellTiter-Glo substrate and
buffer were combined, and 100 μl was added to each well
containing sample. The reagent and cells are mixed for 5
min on a shaker at room temperature. The 96-well plate
was then allowed to rest at room temperature for 10 min-
utes before being analyzed by a Bio-Tek Synergy HT Plate
Reader using the KC4 V3.4 software (Bio-Tek, Winooski,
VT). All samples were analyzed in triplicate.
Reporter-virion production and purification
Reporter-virions were made as described [37]. In brief,
293TT cells were co-transfected with p16llwcha, a bicis-
tronic HPV16 L1 and L2 plasmid and 8frb, the DsRed or
8fwb, the GFP cDNA containing packaging plasmid. Con-
structs and cells were gifts from Drs. Day and Schiller
(National Cancer Institute, National Institute of Health,
Bethesda, MD). Cells were harvested and lysed after 48
hours. Reporter-virions were allowed to mature at 37°C
over night allowing for proper conformation of the capsid
proteins. After a high salt extraction, reporter-virions were
purified on an optiprep gradient (27%–39%) via ultra-
centrifugation. Titer of reporter-virions was determined by
FACS for the percentage of DsRed or GFP positive cells 48
hours after infection. Tritium labelled reporter-virions
were made with the addition of 3H 24 hours post transfec-
tion.
Binding of radioactive reporter-virions
Tritium labelled reporter-virions containing a DsRed
transgene were added to 293 cells on ice for 2 hours to
allow for binding without internalization. The unbound
reporter-virions were removed by washing with 1× PBS.
Cells were harvested in 30 μl 1× PBS, spotted on What-
mann paper and allowed to dry. The samples were fixed in
5% Trichloroacetic acid (TCA) for 20 minutes and precip-
itated in 95% ethanol for 20 minutes. The samples were
analyzed with the LS 6500 Multipurpose Scintillation
Counter (Beckman Coulter, Palatine, IL). All experiments
were repeated using reporter-virions made from different
preparations.
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